Log Out

Short Interest in ATyr Pharma, Inc. (NASDAQ:LIFE) Grows By 5.4%

kopsource · Sep 21, 2022 09:22

aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) was the recipient of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 341,600 shares, a growth of 5.4% from the August 15th total of 324,000 shares. Based on an average daily trading volume, of 131,700 shares, the days-to-cover ratio is presently 2.6 days.

aTyr Pharma Stock Down 3.9 %

aTyr Pharma stock opened at $2.93 on Wednesday. The firm's fifty day moving average price is $3.49 and its two-hundred day moving average price is $3.76. aTyr Pharma has a 1-year low of $2.60 and a 1-year high of $13.10.

Get aTyr Pharma alerts:

aTyr Pharma (NASDAQ:LIFE – Get Rating) last announced its quarterly earnings results on Monday, August 15th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01). During the same quarter last year, the company earned ($0.64) EPS. Analysts anticipate that aTyr Pharma will post -1.81 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Sanjay Shukla bought 15,000 shares of aTyr Pharma stock in a transaction that occurred on Friday, July 1st. The shares were acquired at an average cost of $2.88 per share, for a total transaction of $43,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,798 shares of the company's stock, valued at approximately $117,498.24. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.36% of the company's stock.

Hedge Funds Weigh In On aTyr Pharma

Several large investors have recently bought and sold shares of LIFE. Tikvah Management LLC bought a new stake in shares of aTyr Pharma in the 4th quarter worth $9,157,000. Deep Track Capital LP purchased a new stake in aTyr Pharma in the 4th quarter valued at about $8,217,000. Stonepine Capital Management LLC lifted its position in shares of aTyr Pharma by 28.0% during the 4th quarter. Stonepine Capital Management LLC now owns 525,531 shares of the biotechnology company's stock worth $3,926,000 after buying an additional 114,996 shares in the last quarter. Alyeska Investment Group L.P. boosted its stake in shares of aTyr Pharma by 12.7% in the 1st quarter. Alyeska Investment Group L.P. now owns 760,798 shares of the biotechnology company's stock worth $4,070,000 after buying an additional 85,823 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of aTyr Pharma in the fourth quarter valued at approximately $439,000. 65.58% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on LIFE. Piper Sandler raised their price target on shares of aTyr Pharma from $11.00 to $14.00 and gave the stock an "overweight" rating in a report on Monday, August 15th. StockNews.com lowered aTyr Pharma from a "hold" rating to a "sell" rating in a research report on Wednesday, September 14th. Finally, HC Wainwright increased their price target on aTyr Pharma from $11.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, July 21st.

About aTyr Pharma

(Get Rating)

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.